P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Thomas Martin,Paul G. Richardson,Thierry Facon,Philippe Moreau,Aurore Perrot,Ivan Spicka,Kamlesh Bisht,Marlène Inchauspé,F. Casca,Sandrine Macé,Helgi J. K. Van De Velde,Kenshi Suzuki +11 more
TL;DR: In this paper , the authors propose a method to solve the problem of "not available" data: https://www.youtube.com/watch/watch?feature=youtu.
Journal ArticleDOI
Rifaximin is Efficacious in the Treatment of Chronic Overt Hepatic Encephalopathy: A UK LIVER MULTI-CENTRE EXPERIENCE
Vishal C. Patel,James Orr,John Sturgeon,Z Habtemariam,Helen Preedy,Paul G. Richardson,Richard Aspinall,Mark Hudson,Debbie L. Shawcross +8 more
TL;DR: Rifaximin significantly reduced both hospital re-admission rates after 3 months treatment, impacting significantly on the NHS resource burden of HE, and reduced overall liver disease severity raising the possibility that its therapeutic effect may extend beyond reducing gut ammonia production.
Journal Article
Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.
TL;DR: The pathogenesis and clinical features of VOD are addressed, the role on endothelial cell injury and risk factors are outlined and the current status of research for both treatment and prevention is discussed.
Journal ArticleDOI
Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,David Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven A. Limentani,Melissa Alsina,Dixie-Lee Esseltine,Kenneth C. Anderson +11 more
TL;DR: An updated analysis of overall survival (OS) after prolonged follow-up in patients with relapsed or refractory multiple myeloma with Vc ± dex at both the 1.0 and 1.3 mg/m 2 dose levels suggests that the higher dose of Vc is more active.
Journal ArticleDOI
Depressive symptoms and use of HIV care and medication-assisted treatment among people with HIV who inject drugs.
Oleksandr Zeziulin,Katie R. Mollan,Bonnie E. Shook-Sa,Brett Hanscom,Kathryn E. Lancaster,Kostyantyn Dumchev,Vivian F. Go,Viet Anh Chu,Tetiana Kiriazova,Zulvia Syarif,Sergii Dvoryak,Sarah A. Reifeis,Erica L. Hamilton,Riza Sarasvita,Scott Rose,Paul G. Richardson,William Clarke,Carl A. Latkin,David S. Metzger,Irving F. Hoffman,William C. Miller +20 more
TL;DR: High levels of depressive symptoms were common among PLWH who inject drugs in Ukraine but were less common in Vietnam and Indonesia, and the study intervention was effective among participants with or without baseline depression symptoms.